Answers are grounded in this paper and cite their sources.
The use of histone deacetylase inhibitors (HDACis) to reverse epigenetic silencing of immune‐associated genes has shown clinical efficacy in hematologic malignancies but not solid tumors. Here we explored the transcriptional and phenotypic effects of in vitro exposures of Zabadinostat, a second‐generation class I HDACi, on human peripheral blood mononuclear cells and solid tumor cells to support its combination with immunotherapy. Zabadinostat induced activation of CD8 + and CD4 + T cells and natural killer cells, while reducing the frequency and suppressive function of regulatory T cells. Increases in stem‐like memory T cells, a rare subset of multipotent, self‐renewing cells important for anti‐tumor control, were also observed, and these immune effects coincided with increased expression of transcriptional activation marks H3K9ac and H3K27ac. Zabadinostat increased PD‐L1, FAS, ICAM‐1, and HLA expression in tumor cells and reverted epithelial–mesenchymal transition‐related proteins. These data show that Zabadinostat is a novel immunomodulatory agent with multifaceted effects, capable of enhancing immune effector function, reducing immunosuppression, and improving the visibility of tumor cells to immune‐mediated attack. These findings support the use of Zabadinostat in combination with immunotherapeutic agents.
No takes yet. Share an insight, caveat, or question.
Pitts et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: